Toxicities during therapy with high doses of methotrexate in children with acute lymphoblastic leukemia
Published 2017-07-01
Keywords
- acute lymphoblastic leukemia,
- methotrexate,
- toxic effects
How to Cite
Abstract
Intensification of systemic chemotherapy with incinclusionof high doses methotrexate (MTX) has contributed to the improvement of event-free survival in children with acute lymphoblastic leukemia (ALL). Despite this benefit, this agent might cause serious toxicity, even life-treating events during treatment. Therefore, prediction, early detection and management of toxic effects during therapy with high doses of MTX is still a great challenge for every pediatric oncologist.
The aim of our study was to evaluate the incidence of toxic effects of chemotherapy with high doses of MTX (5 g/m^2) and to compare them with toxicity during application of lower doses of MTX (2 g/m^2).
Retrospective record review of 77 children with medium risk ALL was done. Patients were treated in the Department of hematology and oncology at the University children's hospital in Skopje. Forty-five of them were treated with 5 g/m^2 and 32 of them were treated with 2 g/m^2 (historic group). Toxicity was registered according to the protocol for acute toxicity, part of the ALL BFM 95 protocol.
Toxic effects were predominant in the group treated with higher doses of MTX. The most significant toxic effects were hepatotoxicity, oral mucositis and myelosuppression. More severe grade of hepatotoxicity and oral mucositis were present in the study group. In our study toxic effects were more common in the study group due to application of higher doses of MTX.
Variations in toxicity between the patients of the study group are probably due to the genetic differences in the drug absorption, their excretion and cellular transport. Current studies are dedicated on discovering genetic markers which will be able to predict the risk of appearance of MTX toxicity.
Downloads
References
- Poplack D. Acute lymphoblastic leukemia. Vo: Pizzo P,
- Poplack D, Ed. Principles and practice of Pediatric oncology,
- Lippincot, 1993: 431-483.
- Schrappe M, Pieters R. Acute lymphoblastic leukemia.
- Vo: Pinkerton R, Plowman P, Pieters R, Ed. Pediatric
- oncology, Arnold, 2004, 230-254.
- BFM study group, Treatment protocol ALL-BFM 95 for
- children and adolescents with acute lymphoblastic leucaemia,
- a cooperative multicentar trial of the German society
- for pediatric hematology and oncology, updated English
- version of the original protocol, Novembеr, 10, 1997.
- Schrappe M, Reiter A, Zimmerman M, et al. Long term
- results of four consecutive trials in childhood ALL performed
- by ALL-BFM study group from 1981-1995. Leukemia
- ;14: 2205-22.
- Schmiegelow K. Advances in individual prediction of
- methotrexate toxicity a review. Br J Haematol 2009;
- : 489-503.
- Gauri K, Rupal S, Sarfraz A. Experience with high dose
- methotrexate therapy in childhood acute lymphoblastic
- leukemia in a tertiary care centre of a developing
- country. Pediatr Blood Cancer 2012; 59:448-53.
- Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs
- GT. Comparison of pharmacokinetics and toxicity
- after high-dose methotrexate treatments in children
- with acute lymphoblastic leukemia. Anticancer drugs
- ; 24(2): 189-197.
- Vagace HM, Marzal CC, Jimenez M et al. Methotrexat –
- induced subacute neurotoxicity in a child with acute
- lymphoblastic leukemia carrying genetic polymorfisms
- related to folate homeostasis. Am J Hematol Oncol
- ; 86: 98–101.
- Van Hasselt JGC, van Eijkelenburg NKA, Huitema ADR,
- Schellens JHM, Schouten-van Meeteren AYN. Severe
- skin toxicity in pediatric patient treated with voriconazole
- and concomitant methotrexate. Antimicrobial
- Agents Chemother 2013; 57(6): 2878-81.
- Pietrzyk JJ, Bik-Multanowski M, Balwierz W. et al. Additional
- genetic risk factor for death in children with
- acute lymphoblastic leukemia: A common polymorphism
- of the MTHFR Gene. Pediatr Blood Cancer
- ; 52:364-368.
- Farrow AC, Buchanan GR, Zwiener RJ, Bowman
- WP and Winick NJ. Serum aminotransferase elevation
- during and following treatment of childhood acute
- lymphoblastic leukemia. JCO 1997; 15 (4): 1560-66.
- Evans W, Relling M, Rodman J et al. Conventional
- Compared with Individualized Chemotherapy for Childhood
- Acute Lymphoblastic Leukemia. N Engl J Med
- ; 338:499-505
- De Rotte M.C.F.J, Den Boer E, Bulatovik Calasan M et
- al: Personalized medicine of methotrexate therapy.
- Ned Tijdschr Klin Chem Labgeneesk 2012; 37: 50-53.
- Luisa Garre M, Relling M., Kalwinsky D. et al. Pharmacokinetiks
- and toxicity of methotrexate in children
- with Down syndrome and acute lymphocytic leukaemia.
- J Pediatr. 1987; Volume 111(4): 606-12